Triple immunotherapy with anti-PD-1 mAb, a STING agonist, and anti-LAG-3 mAb further enhanced efficacy compared to any dual immunotherapy regimen, and treatment efficacy was linearly associated with [68Ga]Ga-NOTA-C25 tumor uptake. This evidence concerns the gene PDCD1 and neoplasm.